Padcev
Named-patient access overview. Padcev is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Padcev (enfortumab vedotin) is a Nectin-4-directed antibody-drug conjugate with MMAE payload developed by Astellas and Seagen (Pfizer). It is approved by the US FDA for locally advanced or metastatic urothelial carcinoma in combination with pembrolizumab (first-line, EV-302), as monotherapy after platinum and PD-1/PD-L1 therapy. The standard regimen is 1.25 mg/kg IV days 1 and 8 of 21-day cycle (max 125 mg per dose). Padcev is available in the global pharmaceutical supply chain in 20 mg and 30 mg single-dose vials.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Padcev
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Padcev is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Padcev in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Padcev
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.